Derek Jonker
Ottawa Hospital Research Institute, ON Canada · Ottawa Hospital Research Institute · Ottawa Health Research Institute - General Division
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Derek Jonker as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 20:30 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT02879318 · Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic AdenocarcinomaCanadian Cancer Trials Group · completed · Pancreatic Adenocarcinoma · study chair
- Ph1/Ph2NCT02285816 · MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine With Transgenic MAGE-A3 Insertion in Incurable MAGE-A3-Expressing Solid TumoursCanadian Cancer Trials Group · active not recruiting · Advanced/Metastatic Solid Tumours · study chair
- Ph3NCT01830621 · BBI608 and Best Supportive Care vs Placebo and Best Supportive Care in Pretreated Advanced Colorectal CarcinomaNCIC Clinical Trials Group · completed · Colorectal Carcinoma · study chair
- Ph2NCT01622543 · Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal CancerCanadian Cancer Trials Group · completed · Colorectal Cancer · study chair
- Ph1/Ph2NCT01591421 · P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Metastatic/Advanced RAS-Wild Type Colorectal Cancer.Canadian Cancer Trials Group · completed · Metastatic Colorectal Cancer · study chair
- Ph1/Ph2NCT01394939 · Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal CarcinomaJennerex Biotherapeutics · completed · Colorectal Carcinoma, CRC · principal investigator
- Ph2NCT01237665 · IXO (Irinotecan, Xeloda, Oxaliplatin) in Rectal CancerOttawa Hospital Research Institute · unknown · Rectal Cancer · principal investigator
- Ph1NCT00107250 · AZD2171 + Chemotherapy in Advanced NSCLC, Colorectal Cancer, or Other Cancer Suitable for Treatment With Capecitabine (Non-Small Lung Cancer Patients Closed to Enrollment as 8/9/07)NCIC Clinical Trials Group · completed · Colorectal Cancer, Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific · study chair
- Ph3NCT00079066 · Cetuximab + Best Supportive Care Compared With Best Supportive Care Alone in Metastatic Epidermal Growth Factor Receptor-Positive Colorectal CancerNCIC Clinical Trials Group · completed · Colorectal Cancer, Quality of Life · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-11 20:30 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 20:30 UTC. The ranking covers the 200 most relevant of 79 PubMed records, and a shared surname and initials can bring in a namesake. All 79 on PubMed
- K-ras mutations and benefit from cetuximab in advanced colorectal cancer.N Engl J Med · 20082,963 citationsRCR 65.1
- Cetuximab for the treatment of colorectal cancer.N Engl J Med · 20071,614 citationsRCR 34.7
- 509 citationsRCR 13.5
- Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans.Nature · 2011466 citationsRCR 10.9
- 342 citationsRCR 13.0
- Structured Exercise after Adjuvant Chemotherapy for Colon Cancer.N Engl J Med · 2025305 citationsRCR 81.7
- Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17.Eur J Cancer · 2015268 citationsRCR 7.8
- Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial.Lancet Gastroenterol Hepatol · 2018154 citationsRCR 5.2
- 143 citationsRCR 8.6
- PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17.Clin Cancer Res · 2014140 citationsRCR 3.7